COMMUNIQUÉS West-GlobeNewswire

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
16/06/2026
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by mid-July 2026, with [...]
NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure
16/06/2026
NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure Settlement to eliminate potential dilution from convertible notes [...]
CDT Equity Announces Debt Update and New Loan Facility
16/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all [...]
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
16/06/2026
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. ( [...]
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
16/06/2026
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which [...]
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
16/06/2026
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 [...]
Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
16/06/2026
The agreement with Lovell Government Services creates opportunities to sell the LIBERTY® System at more than 2,000 government facilities, including those administered by the U.S. Department of Veterans Affairs, the [...]
Klow Peptide Stack Introduced by Koi Peptides for Laboratory Research in 2026
16/06/2026
Sheridan, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has introduced Klow Peptide Stack as a research-use-only multi-peptide blend for laboratory research in 2026. The product contains GHK [...]
First Steps Developmental Services Expands School Partnership Program to Support Massachusetts Students and Educators
16/06/2026
Behavior Technician support, BCBA consultation, and school-based behavioral services help Massachusetts schools maintain continuity of support for students during staffing shortages, extended absences, and other [...]
Wolverine Peptide Stack & Blend Introduced by Koi Peptides for Laboratory Research
16/06/2026
Sheridan, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has introduced Wolverine Peptide Stack as a research-use-only peptide stack for laboratory research. The product combines BPC-157 and [...]
Syncromune Presents Multi-Modal Efficacy Assessment Framework at Inaugural Gustave Roussy Intratumoral Immunotherapy Symposium
16/06/2026
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2026 (GLOBE NEWSWIRE) -- Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™, an investigational in situ multi-target [...]
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
16/06/2026
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee and Board of Directors granted Matthew [...]
MultiValent Biotherapies Launches with $27 Million Series A Financing to Advance Development of Targeted Prostate Cancer Drug Conjugate
16/06/2026
- First closing of $27 million Series A financing - - Funding will support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA x FRα) targeted drug conjugate - - [...]
Picard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026
16/06/2026
Two scientific presentations highlight next-generation innovation and patient outcomes with total artificial heart support TUCSON, Ariz., June 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“ [...]
Breckenridge Distillery Celebrates America's 250th Anniversary with the Launch of Patriotic Reserve Bourbon Whiskey
16/06/2026
A limited-release American-crafted whiskey honoring the nation’s milestone anniversary, the spirit of Independence Day, and the veterans and active-duty service members who help protect it BRECKENRIDGE, Colo., June 16, [...]
King Faisal Specialist Hospital Presents Robotic Surgery as a Model for Innovation-Driven Specialized Care at HLTH Europe 2026
16/06/2026
AMSTERDAM, June 16, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) is highlighting its leadership in robotic surgery during its participation at HLTH Europe 2026, taking place from [...]
Le King Faisal Specialist Hospital présente la chirurgie robotique comme modèle de soins spécialisés axés sur l’innovation lors du congrès HLTH Europe 2026
16/06/2026
AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) met en avant son leadership en chirurgie robotique à l’occasion de sa participation au congrès HLTH Europe 2026 [...]
Une famille soutient la recherche sur les cancers rares par l’intermédiaire de la Fondation du CUSM
16/06/2026
MONTRÉAL, 16 juin 2026 (GLOBE NEWSWIRE) -- La générosité d’une famille permet de réaliser une percée majeure dans la recherche sur les cancers rares au CUSM. Dans le cadre du Projet SDR de la Fondation du CUSM, Jim [...]
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
16/06/2026
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard [...]

Pages